Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.

At a glance
Trial Overview
Trial Details
Interventions
Trial Centres
- Investigators
- Centres
Trial History
References

Trial Profile

Characterization of Cerebral Amyloid Deposition With 18F-Flutemetamol PET and of Glucose Metabolism With 18F-FDG PET in Individuals Enrolled in the ALFA Project.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fludeoxyglucose F-18 (Primary) ; Flutemetamol-F-18 (Primary)
Indications Alzheimer's disease
Focus Pharmacodynamics

Most Recent Events

11 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
30 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
08 Jun 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com